Mononucleosis infecciosa en pacientes con enfermedad inflamatoria intestinal en tratamiento con azatioprina

Carrió, Silvia; Bargalló, Ana; Mañosa, Míriam; Domènech, Eugeni; Cabré, Eduard; Gassull, Miquel Àngel; Arévalo, Juan Antonio; Cabriada, José Luis.
Gastroenterol. hepatol. (Ed. impr.) ; 31(5): 289-292, mayo 2008.
Artículo en Español | IBECS (España) | ID: ibc-84645

Documentos relacionados

  1. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases.
  2. Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy.
  3. Importance of NUDT15 c.415C>T phenotype in treatment of inflammatory bowel disease with azathioprine and occurrence of severe myelosuppression: A case report.
  4. Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
  5. Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease.
  6. Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population.
  7. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
  8. Analysis of the NUDT15 gene and metabolites of azathioprine in Japanese patients with inflammatory bowel disease.
  9. Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases.
  10. A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine: a case report and review of literature.